NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS
NATICK, Mass., July 1, 2026 (SEND2PRESS NEWSWIRE) — NeuroDex, a precision diagnostics company specializing in the isolation and analysis of neuron-derived extracellular vesicles (NDEs) from blood, today announced new findings supporting NDE-associated TDP-43 as a treatment-responsive biomarker in amyotrophic lateral sclerosis (ALS).